Table 2.
Patients who filled the questionnaires: younger vs. older patients
| Age < 70 | Age > =70 | p-value | |
|---|---|---|---|
| N | 86 | 23 | - |
| Gender Male: Female | 73:13 | 19:4 | 0.75 |
| Age (years)a | 58 (51–64) | 75 (72–80) | <0.0001 |
| Histotype:b | 0.14 | ||
| Adenocarcinoma | 62 (72.9) | 13 (56.5) | |
| Squamous cell carcinoma | 23 (27.1) | 10 (43.5) | |
| Tumour site: | 0.42 | ||
| Cervical oesophagus | 6 (7.0) | 0 | |
| Thoracic oesophagus | 10 (11.6) | 4 (17.4) | |
| Oesophago-gastric junction | 70 (81.4) | 19 (82.6) | |
| Prognostic nutritional indexa | 49.0 (46.5–52.0) | 48.2 (44.4–50.7) | 0.39 |
| Charlson Comorbidity Indexa | 2 (2–3) | 3 (2–3) | 0.09 |
| Age related Charlson Comorbidity Indexac | 3 (2–4) | 5 (5–6) | <0.0001 |
| Neoadjuvant therapy | 75 (87.2) | 15 (65.2) | 0.03 |
| Type of neoadjuvant therapy: | - | ||
| Chemotherapy | 24 (32.0) | 5 (33.3) | |
| Radiotherapy | 1 (1.3) | 0 | |
| Chemo-radiotherapy | 50 (66.7) | 10 (66.7) | |
| Hospital stay (days)a | 19 (16–24) | 23 (18–30) | 0.04 |
| Pathological staged | 0.07 | ||
| 0 | 23 (26.7) | 2 (8.7) | |
| I | 16 (18.6) | 4 (13.0) | |
| II | 14 (16.3) | 10 (43.5) | |
| III | 29 (33.7) | 7 (30.4) | |
| IV | 4 (4.7) | 1 (4.4) | |
| Post-operative morbidity | 20 (23.3) | 9 (39.1) | 0.18 |
Data expressed as n (%) or amedian (IQR)
bOther histotype in one patient
cComparison biased due to age penalization in score calculation
dPathological stage is ypstage for patients who received neoadjuvant therapy and pstage for patients who did not